CMBA
ENTA icon

C.M. Bidwell & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

C.M. Bidwell & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18K Buy
+331
New +$4.44K ﹤0.01% 345
2022
Q1 		– Sell
-1,143
Closed -$85K – 557
2021
Q4 		$85K Buy
+1,143
New +$89.7K 0.05% 249

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

C.M. Bidwell & Associates's ENTA Position: Q1 2026 in Review

C.M. Bidwell & Associates opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2026: 331 shares worth $4.18K. The stake represents ﹤0.01% of the portfolio and ranks #345 among its holdings. This is a return to the name: C.M. Bidwell & Associates previously reported a position in ENTA as recently as Q4 2021.

C.M. Bidwell & Associates first reported a position in ENTA in Q4 2021 and has held it in 2 quarters since. The position peaked at $85K in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • C.M. Bidwell & Associates held 331 shares of Enanta Pharmaceuticals worth $4.18K as of Q1 2026.
  • Enanta Pharmaceuticals was a new C.M. Bidwell & Associates position in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #345 holding.
  • C.M. Bidwell & Associates first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • C.M. Bidwell & Associates's Enanta Pharmaceuticals position peaked at $85K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.